Adrenaline [1], hypercalcemia ---> SmPC of [1] of eMC
If the calcium level is increased, use of adrenaline may lead to severe cardiac arrhythmia.
Amlodipine/valsartan/hydrochlorothiazide [1], hypercalcemia ---> SmPC of [1] of EMA
Dafiro HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Dafiro HCT should be discontinued if hypercalcaemia develops during treatment.
Bendroflumethiazide, hypercalcemia
Decreased urinary excretion of calcium salts
Calcifediol, hypercalcemia
Increased effect of calcifediol
Digitoxin, hypercalcemia
Increased effect of digitoxin and risk of digitoxin intoxication. The calcium should not be administered intravenously.
Digoxin, hypercalcemia
Hypercalcemia predisposes to digitalis toxicity
Dihydrotachysterol, hypercalcemia
The co-administration of dihydrotachysterol and calcium salts may cause hypercalcemia
Diltiazem, hypercalcemia
Hypercalcemia may decrease the effect of diltiazem
Hypercalcemia, metildigoxin
Increased plasma levels of metildigoxin
Hypercalcemia, paricalcitol [2] ---> SmPC of [2] of eMC
Digitalis toxicity is potentiated by hypercalcaemia of any cause, so caution should be applied when digitalis is prescribed concomitantly with paricalcitol
Hypercalcemia, thiazides
Thiazide diuretics reduce urinary calcium excretion so the risk of hypercalcaemia should be considered.
Hypercalcemia, thiazides ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
Thiazides reduce urinary calcium excretion and may cause intermittant and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.
Hypercalcemia, toremifene [2] ---> SmPC of [2] of EMA
Drugs which decrease renal calcium excretion, e.g. thiazide diuretics, may increase the risk of hypercalcaemia.
Hypercalcemia, vitamin D
Increased risk of hypercalcaemia